secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2022-06-15T23:59:59+00:00
Accession:  0000950170-22-011646
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics stockholders elect three Class I directors, ratify auditor at 2022 annual meeting
--------------------------------------------------------------------------------

- David Campbell, Ron Barrett, and Stefan Heller elected as Class I directors with 33.9M, 34.7M, and 33.9M votes for, respectively.
- Ernst & Young LLP ratified as independent auditor for FY2022 with 37.85M votes for, 3 against, 244 abstentions.
- Broker non-votes of 2,998,529 on all director elections; none on auditor ratification.
- Total outstanding shares as of record date April 18, 2022: 41,629,367.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017022011646/0000950170-22-011646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017022011646/janx-20220614.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-011646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer